The Subcutaneous Drug Delivery Devices Market Size is valued at USD 30.9 Bn in 2023 and is predicted to reach USD 55.7 Bn by the year 2031 at an 7.9% CAGR during the forecast period for 2024-2031.
Subcutaneous drug delivery devices are specific systems designed to deliver drugs directly into the subcutaneous tissue, that is, just below the skin. Examples include syringes and autoinjectors to wearable infusion pumps for medicines that require absorption slowly into the bloodstream. SC injections are administered for a wide range of therapeutic applications; these include chronic conditions such as diabetes (insulin) and autoimmune diseases (biologics), emergency treatments such as EpiPens for allergic reactions, and some vaccinations. This administration route is very convenient for self-administration.
Increasing demand for self-administration is one of the primary driving factors behind this expansion of subcutaneous drug delivery devices in the market. Patients are growing to seek methods that would allow them to manage their treatments at home, thus reducing their frequent visits to healthcare facilities and increasing adherence to prescribed regimens. This is congruent with the increasing trend of personalized medicine and even home healthcare solutions, quite convenient for enhanced patient comfort, necessary both for healthcare providers and patients.
Competitive Landscape
Some of the Key Players in Subcutaneous Drug Delivery Devices Market:
- Gerresheimer AG
- Medtronic Plc
- Ypsomed AG
- Elcam Medical Group
- Novo Nordisk
- Insulet Corporation
- Becton, Dickinson and Company
- West Pharmaceutical Services, Inc.
- PharmaJet
- Unilife Corporation
- Inolife Sciences
Market Segmentation:
The subcutaneous drug delivery devices market is segmented by product, distribution channel. By product the market is segmented into prefilled syringes, pen injectors, auto injectors, wearable injectors, needle-free injectors. By distribution channel market is categorized hospital pharmacies, retail pharmacies, online pharmacies.
Prefilled Syringes is Expected to Drive the Subcutaneous Drug Delivery Devices Market
Increase in use of prefilled syringes is one of the most important drivers for market growth of the subcutaneous drug delivery devices. Since the syringes already have medication, the administration procedure is much easier with fewer chances to make dosing errors. This is particularly valuable for self-administration, where injections can be conducted on an impromptu basis with no need for elaborate training. Prefilled syringes also ensure the safety of patients through accurate dosing and minimizing contamination and needle-stick injuries risks, among other benefits that improve treatment outcomes and compliance. While they cost more upfront, they can save money in the long term by minimizing wastage of drugs, estimated to be 20-30% less than vials, and repeated visits to the healthcare system, which subsequently save money.
Online Pharmacies is Growing at the Highest Rate in the Subcutaneous Drug Delivery Devices Market.
Online pharmacies are developing quickly as the fastest-growing distribution channel in the subcutaneous drug delivery devices market, driven by convenience, privacy, and cost-effectiveness. The platform offers patients, including chronic patients, the added convenience to order drugs from home, thereby avoiding frequent trips to physical stores. The discreet shopping experience appeals to the individual purchasing sensitive medications, and competitive pricing and promotions render the platform appealing to the cost-conscious consumer. For example, the better are the online health services, including consulting and prescription management, the greater the usability and confidence in the online shopping process.
Regionally, North America Led the Subcutaneous Drug Delivery Devices Market.
At present, North America dominates the subcutaneous drug delivery devices market. Its highly developed health care infrastructure, high rates of chronic diseases, massive investment in medical technologies, and strong reimbursement systems are the key factors influencing demand for this market. Established healthcare centers and access to state-of-the-art medical services in this region enable the mass use of innovative subcutaneous drug delivery systems. Increasing numbers of patients suffering from chronic diseases, such as diabetes and rheumatoid arthritis, increase demand for these devices. The leading pharmaceuticals industry in North America invests considerably in R&D to accelerate drug delivery technologies. Complete healthcare reimbursement policies also ensure patient access and adoption.
Subcutaneous Drug Delivery Devices Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 30.9 Bn |
|
Revenue Forecast In 2031 |
USD 55.7 Bn |
|
Growth Rate CAGR |
CAGR of 7.9 % from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Product, By Distribution Channel, and By Region |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South Korea; Southeast Asia |
|
Competitive Landscape |
Gerresheimer AG, Medtronic Plc, Ypsomed AG, Elcam Medical Group, Novo Nordisk, Insulet Corporation, Becton, Dickinson and Company, West Pharmaceutical Services, Inc., PharmaJet, Unilife Corporation, Inolife Sciences |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Geographic competitive landscape. |
|
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
